Memory CD8 T cells to influenza A viruses are widely detectable in healthy human subjects and broadly cross-reactive for serologically distinct influenza A virus subtypes. However, it is not clear to what extent such pre-existing cellular immunity can provide cross-subtype protection against novel emerging influenza A viruses.
We show in the mouse model that naturally occurring sequence variations of the conserved nucleoprotein of the virus significantly impact cross-protection against lethal disease in vivo. When priming and challenge viruses shared identical sequences of the immunodominant, protective NP366/Db epitope, strong cross-subtype protection was observed. However, when they did not share complete sequence identity in this epitope, cross-protection was considerably reduced. Contributions of virus-specific antibodies appeared to be minimal under these circumstances. Detailed analysis revealed that the magnitude of the memory CD8 T cell response triggered by the NP366/Db variants was significantly lower than those triggered by the homologous NP366/Db ligand. It appears that strict specificity of a dominant public TCR to the original NP366/Db ligand may limit the expansion of cross-reactive memory CD8 T cells to the NP366/Db variants.
Pre-existing CD8 T cell immunity may provide substantial cross-protection against heterosubtypic influenza A viruses, provided that the priming and the subsequent challenge viruses share the identical sequences of the immunodominant, protective CTL epitopes.
Citation: Zhong W, Liu F, Dong L, Lu X, Hancock K, Reinherz EL, et al. (2010) Significant Impact of Sequence Variations in the Nucleoprotein on CD8 T Cell-Mediated Cross-Protection against Influenza A Virus Infections. PLoS ONE 5(5): e10583. doi:10.1371/journal.pone.0010583
Editor: Robyn Klein, Washington University, United States of America
Received: March 2, 2010; Accepted: April 19, 2010; Published: May 11, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported, in part, by a pilot project grant to WZ from National Institutes of Health (U19 AI50900. Project Director: ELR). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Infection with one subtype of influenza A virus often results in a strong protection against subsequent infections with heterosubtypic influenza A viruses in animal models. This type of immunity, termed heterosubtypic immunity , is unable to prevent infection per se, but can considerably reduce viral load, leading to an accelerated recovery from influenza illness . Heterosubtypic immunity is a necessary component of a so-called “universal” influenza vaccine that would provide protection against illness from multiple subtypes of influenza A viruses.
Optimal heterosubtypic immunity is thought to be dependent on multiple components of the immune system. This includes T cells, especially the CD8 T cell subset that recognizes CTL epitopes derived from the conserved internal proteins of the virus such as nucleoprotein (NP) and matrix protein 1 (M1) , haemagglutinin (HA)-specific mucosal IgA antibodies , and serum antibodies specific for the ecotodomain of the highly conserved matrix protein 2 (M2) , and possibly, HA-specific antibodies that recognize conserved B cell epitopes of the molecule , . Extensive studies in the mouse model have demonstrated that one or other component of the immune system may play a dominant role under different circumstances. For example, many studies have shown that CD8 T cells are the major mediator of heterosubtypic immunity following intranasal priming of immune competent mice with live influenza virus particles –. On the other hand, heterosubtypic immunity was not observed in B cell-deficient mice, although the same challenge route was used and cross-reactive CTLs were detectable in these animals .
Seasonal influenza A H1N1 and H3N2 viruses have been circulating in humans for many years . As a result, peripheral blood memory T cells that are broadly cross-reactive, not only against serologically distinct seasonal influenza A viruses but also avian H5N1 influenza viruses, can be demonstrated in healthy individuals –. As a majority of influenza virus-specific memory CD8 T cells are directed against the conserved NP and M1 protein , it has long been proposed that pre-existing memory CD8 T cells should, in principal, provide some degree of cross-protection against disease during the emergence of a new pandemic influenza A virus in humans. However, although CD8 T cell mediated heterosubtypic protection is relatively efficient in animal models, such immune benefit remains unclear in humans. Recent analysis of the historic epidemiological data suggests that prior exposure to H1N1 influenza virus resulted in generation of protective immunity against heterosubtypic H2N2 virus . A variety of NP and/or M1-based novel vaccination strategies are currently under evaluation for their efficiency to induce T cell immunity-based protection against heterosubtypic influenza A viruses , . However, even the more conserved internal proteins of influenza A viruses, including the NP, undergo evolutionary change , . Consequently, multiple CD8 CTL epitope variants have been identified in circulating seasonal influenza A viruses , . In vitro studies have showed that certain human CD8 CTL clones generated were able to recognize CTL epitope variants derived from both homo- and heterosubtypic influenza A viruses . The impact of such sequence variations on CD8 T cell-mediated heterosubtypic immunity in vivo has not been examined previously.
In the present study, we assessed the ability of cross-reactive memory CD8 T cells to the immunodominant, protective NP366/Db CTL epitope to confer protective heterosubtypic immunity under circumstance where priming and subsequent challenge influenza A viruses do or do not share sequence identity of the CTL epitope. Our results reveal that sequence variations in the NP of influenza A viruses can significantly impact heterosubtypic protection mediated by the NP366/Db-specific memory CD8 T cells in vivo, under circumstances in which virus-specific serum HI antibodies, nasal IgA and serum M2-specific antibodies were unlikely to impact on the protective heterosubtypic immunity.
Results and Discussion
In the present study, we chose the C57BL/6 (B6) mouse model to assess the extent of heterosubtypic immunity based on the following considerations: (1) Both CD8 and CD4 T cell epitope repertoire of influenza A virus have been extensively characterized in B6 mice and a Db-restricted, immunodominant NP366 epitope is the major target to mediate a protective, memory CTL response after secondary infections with influenza A viruses –. (2) Analysis of the deduced amino acid sequences of the NP gene from a large number of influenza A viruses (955 sequences), indicated that, certain amino acid residues within the NP366/Db CTL epitope undergo constant evolutionary change (Table 1), despite the overall conserved nature of this internal protein between different influenza A virus subtypes (∼89% identity among sequences analyzed). A total of ten naturally occurring NP366 variants were identified, each representing a different subtype of influenza A virus. Of interest, all of the amino acid substitutions observed were located at the C-terminal bulge of the NP366 peptide backbone, the featured structural region of the NP366/Db complex exposed for recognition by the TCRs of CD8 T cell subset induced by influenza A virus infection . (3) Except for the NP366/Db epitope, each panel of heterosubtypic influenza A viruses used for priming and secondary challenge in the present study share identical immunodominant MHC class II T cell epitopes and all other known class I T cell epitopes (Table S1 and Table S2). Such a combination of priming and challenge viruses offers an unique opportunity to dissect the impact of NP366/Db epitope sequence variation on memory CD8 T cell-mediated protective heterotypic immunity in B6 mice.
Heterosubtypic protection is significantly decreased when challenge influenza A viruses do not share identical NP366/Db CTL epitopes as the priming virus
We first evaluated the extent of heterosubtypic protection against lethal challenge with viruses that do or do not share the identical NP366/Db CTL epitope as the priming viruses. As expected from previous studies , , mice that were primed by intranasal infection with X31 virus (H3N2) did not show any body weight loss following intranasal challenge with a low lethal dose (3 LD50) of heterosubtypic PR8 virus (H1N1) that shares complete sequence identity in the NP366 CTL epitope with X31 virus (Fig. 1, upper panel). To further evaluate the robustness of the heterosubtypic protection induced under this circumstance, a second group of X31-primed mice received a 10-fold higher lethal challenge dose (30 LD50) of PR8 virus. Even in this case, X31-primed mice exhibited only modest and transient weight loss on day five after the lethal viral challenge (maximum mean weight loss: ∼5%) and rapidly regained the weight to normal levels by day seven post-challenge. All X31-primed animals survived challenge with either lethal dose of PR8 virus. In contrast, mice that were primed by NT60 virus (H3N2) and then challenged with 3 LD50 of PR8 virus, lost approximately ∼10% of body weight between day 7 and 9 post-challenge. When a second group of NT60-primed mice were challenged with high lethal dose (30 LD50) of PR8 virus, mice experienced severe weight loss. Only 50% of the mice survived in this group of animals. Control mice challenged with either doses of PR8 virus experienced substantial and rapid weight loss and succumbed to between day five and seven post-challenge. Thus, compared with the control mice, priming with NT60 virus can confer substantial level of cross-protection when the challenge dose of the heterosubtypic PR8 virus was low. However, severe body weight loss was observed in the group of NT60 virus-primed animals when high lethal dose of the PR8 virus was administered. One explanation for the results described above is that the robust cross-subtype protection conferred by priming with X31 virus is simply due to the ability of the virus to replicate more extensively in the lung of B6 mice compared to NT60 virus (the mean peak lung virus titers are approximately 107 and 105 EID50/lung, respectively), which may in turn stimulate a stronger memory immune response after priming. To rule out this possibility, we tested the ability of the X31 virus to induce cross-subtype protection against challenge with Taiwan virus (H1N1), where the NP366 epitope sequences between the two viruses differ by only one amino acid residue at the C-terminal bulge of the peptide-Db ligand (Table 1). A different H3N2 priming virus, Memphis, was also used because it shares complete identity in NP366/Db epitope sequence with Taiwan virus and replicates to a similar extent in B6 mouse lungs as the NT60 virus (mean peak lung virus titer: 105 EID50/lung). As shown in Fig. 1, lower panel, priming with the Memphis virus conferred robust protection against either a low (3LD50) or high (9 LD50) lethal dose challenge of the heterosubtypic Taiwan virus. Note that the latter is the maximum lethal challenge dose achievable for this virus. In contrast, cross-protection against the Taiwan virus was significantly reduced in X31-primed mice.
Five to eight B6 mice per group were primed intranasally with X31 or Memphis H3N2 influenza A viruses as indicated or equal volume of allantoic fluid as control. 35 to 45 days after priming, the animals were challenged with lethal doses of heterosubtypic H1N1 influenza viruses as indicated. Body weight loss (left panel) and survival (right panel) of the animals were monitored until day 19 after lethal challenge. Animals that lost 25% of their initial body weight were considered moribund and sacrificed according the animal protocol. The results were expressed as body weight loss of individual mice per group. The numbers on the lower right corner of each graph indicate survival rate of each group (the number of animals survived/total number of animals tested).
Together, these results support previous observations demonstrating that priming with one subtype of live influenza A viruses can results in significant protection against subsequent infections with a different subtype of influenza A viruses -. Moreover, our results suggest that optimal protective heterosubtypic immunity conferred by CD8 T cells is only achieved when priming and challenge virus share the identical immunodominant CTL epitope(s). When the challenge viruses do not share the identical CTL epitopes with the priming viruses, the degree of heterosubtypic immunity against different subtypes of influenza A viruses appears to depend on the challenge dose. Complete cross-protection from death can be achieved, if the challenge dose is low, but protective heterosubtypic immunity is considerably reduced in the face of a high lethal challenge dose.
Decreased heterosubtypic immunity is not primarily correlated to mucosal and serum antibodies, but to CD8 T cell subset
It has become increasingly clear that both T cell and B cell arms of the immune system may contribute to heterosubtypic immunity after influenza A virus infection, depending on the experimental systems used. In the present study, we used immune competent B6 mice in conjunction with intranasal priming and challenge to assess the capacity of the heterosubtypic immunity. It is possible that the differential capacity of the heterosubtypic immunity observed under this circumstance may be attributed to either the B cell or T cell arm of the immune system, or both.
To distinguish these possibilities, we first examined the possible correlation between serum HA-specific antibodies and heterosubtypic immunity. As expected, priming of B6 mice with either X31 or Memphis virus intranasally resulted in a robust serum antibody response to the homologous strains of the H3N2 viruses (Fig. 2A). Thirty-five days after the priming, serum HI geometric mean titers (GMT) to the homologous X31 and Memphis virus reached to 320 and 184, respectively. However, no subtype cross-reactive serum HI antibodies were detectable to the heterosubtypic Taiwan H1N1 virus following intranasal priming with either live H3N2 virus. Control mice did not show any detectable HI titers against any of the three influenza A viruses tested. These observations are consistent with the generally accepted understanding that serum HI and neutralizing antibodies to the HA glycoprotein of influenza A viruses are subtype-specific and their role in heterosubtypic immunity is minimal under normal circumstances.
Five B6 mice per group were primed intranasally as described in figure 1. Serum, lung and nasal washes were sampled from individual animals at day 37 after priming and tested for serum HI titers (A), nasal wash IgA titers (B), lung wash IgG titers (C) against homotypic as well as heterosubtypic influenza A viruses as indicated. Serum IgG antibody titers to M2 protein was determined by an ELISA using synthetic M2e peptide as antigen (D).
We next examined whether IgA antibodies on the surface of the upper and lower respiratory tract of the primed mice contributed to heterosubtypic immunity following a lethal challenge. Fig. 2B shows that nasal washes obtained 35 days after priming with either X31 or Memphis virus contained IgA antibodies reactive to their homologous virus, although the GMT titers were low (32 and 8, respectively). However, cross-reactive nasal IgA antibodies to the heterosubtypic Taiwan H1N1 virus were not detected following intranasal priming with either H3N2 viruses. Similar results were obtained when lung IgG antibodies from the same animals were examined by a whole virus-ELISA, except that the amount of cross-subtype IgG antibodies to the Taiwan H1N1 virus were equally evident in the lung washes of both groups of the animals (Fig. 2C). Given that HA and NA from X31, e.g. A/Aichi/2/68, and A/Memphis/102/72 virus share high sequence identity (HA1: 96.6%, NA: 94.4%, respectively), it is not surprise that approximately equivalent amount of cross-subtype IgG antibodies to the Taiwan H1N1 virus were detected in the lung washes of both groups of the animals (Fig. 2C. GMT: 588 after priming with X31 versus 256 after priming with Memphis virus, respectively). Thus, neither nasal IgA nor lung IgG appeared to correlate with the differential capacity of the heterosubtypic immunity induced (Fig. 1).
Increasing evidence suggests that M2-specific antibodies induced by vaccination can provide cross-subtype protection against influenza A virus infections . We monitored the levels of serum anti-M2 antibodies after priming with either X31 or Memphis virus using an M2e peptide-based ELISA. As shown in Fig. 2D, although M2-specific antibodies were detected, the GMT titers were low (35 after X31priming and only 5 after Memphis priming, respectively) and highly variable among individual mice. Therefore, we found no correlation between the levels of serum M2-specific antibodies induced by intranasal infection priming and the cross-subtype protection.
Next we examined the effect of T cell subset depletion on the capacity of heterosubtypic immunity described above. As shown in Fig. 3A, mock-primed animals experienced substantial body weight loss following lethal challenge with 9LD50 of Taiwan virus. All of the animals succumbed to infection by day 7 after lethal challenge, independent of CD8 or CD4 T cell depletion in vivo. In contrast, consistent with the results shown in Fig. 1, priming with Memphis virus led to strong resistance to subsequent lethal challenge with 9 LD50 of Taiwan virus (Fig. 3B). However, when the CD8 T cell subset was depleted in vivo from the Memphis-primed animals, significant weight loss was observed on day 5 after lethal challenge (mean percentage of original body weight: 92.3% versus 82.9% when PBS control was compared with CD8-depleted group, p = 0.0079). Depletion of CD4 T cell subset also resulted in slightly more severe weight loss compared to the PBS control group (90.2% versus 92.3%), but the difference was statistically not significant (P = 0.0952). Note that when compared to PBS-treated naïve animals, mice that was primed with Memphis virus and depleted of memory CD8 T cells showed significantly higher degree of cross-protection on day 5 after challenge with heterosubtypic Taiwan H1N1 virus (Mean body weight loss: 77.4% versus 82.9%, respectively. P = 0.0389). This is consistent with previous observation that primed CD4 T cell subset may also provide certain degree of cross-subtype protection under certain circumstances .
Five B6 mice per group were primed intranasally as described in figure 1. Mock-primed (A) or Memphis virus-primed (B) animals were depleted of either CD8- or CD4 T cell subset in vivo as described in Materials and Methods. Monitoring of body weight loss after lethal challenge with Taiwan virus and expression of the results were described in detail in figure 1. One representative result is shown from two independent studies with similar results. Asterisk (*) indicates a statistically significant difference when CD8-depleted group was compared with PBS control group.
These results provide further evidence that multiple components of the immune system may be involved in the cross-subtype protection against heterosubtypic influenza A viruses, but CD8 T cell functions may be most closely correlated with heterosubtypic protection induced following intranasal inoculation with live influenza A virus.
Decreased capacity of the heterosubtypic immunity is correlated with significantly reduced magnitude of the cross-reactive memory CD8 T cell response to the NP366/Db variants
Early data obtained using 51Cr-release assay revealed that influenza virus-specific CD8 T cells are in general highly cross-reactive , . However, the magnitude of cross-reactive CD8 T cell responses to influenza virus CTL epitope variants has not been quantitatively studied in the context of heterosubtypic immunity in vivo. We thus used a dual MHC class I tetramer technique to quantify the total numbers of the NP366/Db -specific CD8 memory effector cells in the lung and the spleen of the mice following the sequential influenza A virus infection. As shown in Fig. S1A, flow cytometric analysis confirmed the specificity and cross-reactivity of these tetramers to homologous and heterologous NP366/Db variants. As shown in Fig. 4A, priming with X31 virus followed by challenge with PR8 virus led to a massive expansion of the PR8-NP366/Db -specific CD8 T cells in the lungs of the animals on day 5 post-challenge (6.94×105 cell/lung). However, when NT60-primed mice were challenged with PR8 virus, the total number of tetramer-positive cells detected in the lungs was significantly lower (0.84×105 cell/lung) compared with those obtained following X31-PR8 virus sequential infection (p = 0.0006). Similar results were obtained when X31-Taiwan virus sequential infection was performed. A detailed analysis of the compositions of the NP366/Db tetramer-positive memory effector cell populations showed that following X31-PR8 virus sequential infection, over 95% of the responding memory CD8 T cells were directed to the NP366/Db epitope shared by both virus strains (Fig. 4B and Fig S1B). CD8 T cells cross-reactive to the NT60-NP366/Db variant were detectable, but at a very low frequency (<5%). In contrast, following either NT60-PR8 or X31-Taiwan sequential infection, the majority of the responding memory effector cells were cross-reactive to both the priming and challenge NP366/Db epitope. In either case, only a small proportion of the cells were specific for the respective priming and the challenge NP366/Db epitope. It is intriguing to note that the percentage of the CD8 T cells specific for the priming NT60-NP366/Db epitope was considerably higher than those specific for the challenge PR8-NP366/Db variant (24.5% versus 6.4%) following the NT60-PR8 sequential infection. However, such a biased memory CD8 T cell response was less pronounced following X31-Taiwan sequential infection (19.2% of X31-NP366/Db+CD8+ cells versus 14.2% of Taiwan-NP366/Db+CD8+ cells). These data clearly demonstrate that the quantity of the cross-reactive memory CD8 T cells is considerably diminished when priming and challenge viruses lack complete sequence identity of the NP366/Db CTL epitope. Preliminary data indicate that the functional quality of the different subsets of the NP366/Db memory effector cells may not differ considerably, as detection of intracellular IFNγ secretion following restimulation of the CD8 T cells with the homologous as well as the NP366 variant peptides did not reveal substantial differences for any population tested.(Fig. S2).
Five to ten B6 mice per group were primed and challenged with lethal doses of heterosubtypic influenza A viruses as described in figure 1. Lung tissues were collected from individual animals five days after the lethal challenge and examined for the magnitude of the CD8 T cell response to the wild-type and variant NP366/Db epitope (A). The mean percentages of the cell subsets from the same set of the data were used to assess the composition of the NP366/Db response specific for the original NP366 priming sequence or cross-reactive to the NP366 challenge variants as indicated (B).
Together with the observations described above (Fig. 1 and 3), these results clearly indicate that the capacity of the heterosubtypic immunity mediated by the NP366/Db CD8 T cells is closely associated with the sequence similarities between the priming and the subsequent challenge NP366/Db epitopes. If both epitopes bear the identical NP366 sequence, strong heterosubtypic immunity can be anticipated, primarily owning to a robust expansion of the memory CD8 T cells triggered by the homologous challenge NP366/Db epitope. When the challenge viruses do not share the identical sequence of the NP366/Db epitopes with the priming viruses, two important factors may contribute to the reduced hetersubtypic immunity. First, considerably reduced expansion of the cross-reactive NP366/Db cells triggered by the heterologous challenge NP366/Db variants (Fig. 4). Another factor may be a biased memory CD8 T cell response toward the priming NP366/Db, but not the challenge NP366/Db epitope, as was observed with the NT60-PR8 sequential infection (Fig. 4B). The reason for this phenomenon is not clear at present. It is possible that CTL original antigenic sin may exist under this circumstance. So far, this phenomenon has been only documented after infection with lymphocytic choriomeningitis viruses  or Dengue virus . More comprehensive studies are needed to ascertain whether the phenomenon observed after NT60-PR8 sequential infection represents a generic CTL original antigenic sin phenomenon in the influenza A virus system, as such a phenomenon was not observed following a sequential delivery of X31-NP366 and Taiwan-NP366, which differ in one amino acid residue at position 7 of the NP366/Db epitope.
Limited plasticity of a dominant public TCR to the heterologous NP366/Db variants may contribute to the decreased expansion of the cross-reactive memory CD8 T cells
The data thus far suggest a limited TCR plasticity of the NP366/Db -specific memory CD8 T cells for heterologous NP366/Db variants. We and others have observed previously that public TCRs are strongly selected following a primary influenza A virus infection in B6 mice (up to 50%) , . As a dominant public TCR that recognizes PR8-NP366/Db epitope has been functionally expressed in the form of a stable transfectant , this allowed us to dissect to what extent the public TCR can cross-react to the naturally occurring NP366/Db variants identified from the bank of NP sequences (Table 1). As shown in Fig. 5A, with the exception of the NP366ET-DN amino acid substitutions, all of the NP366 variants bound to the Db molecule with similar high affinity. Surprisingly, when the ability of the public TCR to recognize these NP366 peptide variants was examined, only the cognate NP366/Db ligand derived from the NP of the PR8 virus was able to trigger the activation of the TCR transfectant (Fig. 5B). Interaction between the nine NP366 peptide variants and the public TCR did not result in the production of IL-2 under the same experimental conditions. These results indicate that the high frequency of the public TCR in the memory CD8 T cell repertoire cannot tolerate any substitutions of the TCR contact residues within the original NP366 peptide sequence. Even a single conserved residue replacement at position 7 (D-E7) completely abolished the productive interaction between the TCR and the variant NP366/Db ligands, as observed in the case of the Taiwan-NP366/Db ligand (Table S1). It is conceivable that such a stringent requirement for sequence identity between the public TCR and its original NP366/Db ligand may considerably reduce the cross-reactivity of memory CD8 T cells following re-infections with heterosubtypic influenza A viruses bearing NP366/Db variants.
Serially titrated amount of synthetic NP366/Db peptides identified in table 1 were used to stabilize Db expression on the surface of a TAP-deficient RMA-S cells in an RMA-S assay (A). The results were expressed as mean fluorescence intensity (MFI). The ability of the NP366/Db variants to trigger activation of a T cell transfectant (clone A3-4) expressing the dominant public TCR specific for the PR8-NP366/Db ligand, was assessed by an IL-2 assay (B). The data are representative of two independent experiments.
Taken together, our results reveal a significant limitation of an important immune effector responsible for heterosubtypic immunity to influenza A virus infection. We found that following primary infection, a high frequency of the NP366-specific memory T cells generated used the public TCRs that are strictly specific for the priming NP366/Db epitope sequence. Upon re-exposure to heterosubtypic viruses that share the identical NP366 epitope sequence with the priming strain, robust memory CD8 response to the initial NP366/Db ligand were obtained, leading to the generation of strong heterosubtypic immunity. However, if the challenge virus does not share the identical NP366 epitope sequence with the priming virus, expansion of the pre-existing, cross-reactive memory CD8 T cells may be limited, either due to their low frequency in the memory CD8 cell repertoire or possibly, a CTL original antigenic sin phenomenon under certain circumstances. Consequently, the heterosubtypic immunity generated is significantly reduced. This implies that efforts to promote CD8 T cell immunity-based vaccination strategies against heterosubtypic influenza A viruses may be most effective, only when the priming and the protective CTL epitopes targeted share the identical epitope sequences. Our findings re-emphasize that multiple immune components may be required for development of broad-protective influenza vaccines.
Materials and Methods
All animal research conducted in the present study was approved by CDC's Institutional Animal care and Use Committee (Approval number: 1619) and in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited facility.
Influenza A viruses and infection
The influenza A viruses used in this study were the H3N2 viruses X31, a reassortant virus possessing the surface HA and NA glycoprotein of A/Aichi/2/68 (H3N2) and six internal genes of A/Puerto Rico/8/34 (H1N1; PR8), A/Northern Territory/60/68 (NT60), A/Memphis/102/72 (Memphis) and the H1N1 viruses PR8 and A/Taiwan/01/86 (Taiwan). All viruses were propagated in the allantoic cavity of 10-day old embryonated chicken eggs. All of the viral stocks were titered for HA units and 50% egg infectious dose (EID50). In addition, the 50% mouse infectious dose (MID50) and 50% lethal dose (LD50) for C57BL/6 (B6) mice were determined for the H3N2 and H1N1 viruses, respectively (Table S3).
Female B6 mice were purchased from Taconic (Albany, NY) and were used at 6-10 weeks of age. For priming, mice were inoculated intranasally with 250 MID50 of an H3N2 virus using Avertin as anesthesia. Between 35 and 45 days later, a time point where the memory T cells are generally considered to have established, the primed mice were challenged intranasally with lethal doses of H1N1 viruses as indicated. Mice that lost 25% of their original body weights were considered moribund and euthanized.
Sera and tissue sampling
Immune sera from mice were collected from the orbital plexus on day 35–45 after priming. To collect lung and nasal washes, mice were sacrificed and the trachea was exposed. An 18-gauge cannula attached to a 1-ml syringe was inserted into the lungs through the incision in the trachea. The lungs were flushed repeatedly with a 1-ml volume of PBS buffer containing 1% bovine serum albumin. Nasal wash samples were recovered by flushing 1 ml of the PBS buffer through the tracheal incision forwarded into the nasal passage. The fluid expelled through the nares was collected in a petri dish and was flushed through the nose two more times. Lung and spleen tissues were sampled at the indicated time points and processed to give single cell suspensions for flow cytometry analysis as described previously .
NP366 peptides were synthesized either at New England Peptide, Inc., Fitchburg, MA, or at Division of Research Resources, CDC, Atlanta, GA. The purity of the synthesized peptides was >96%, as determined by HPLC analysis. All peptides had expected masses as confirmed by mass spectrometry.
Influenza serology assays
Sera were treated with receptor-destroying enzyme from Vibrio cholerae (Denka-Seiken, Tokyo, Japan) before testing for the presence of H1 and H3-specific antibodies . The hemagglutination-inhibition (HI) assay was performed using 4 hemagglutinating units of virus and 0.5% turkey red blood cells . IgG and IgA antibodies were detected by an ELISA using sucrose gradient centrifugation purified viruses as antigens as described previously . The ELISA end-point titers were expressed as the highest dilution that yielded an OD greater than the 2 times mean OD plus SD of similarly diluted negative control samples.
In vivo depletion of CD8 and CD4 T cells
Mice were injected i.p. every third day either with 500 µg of purified rat anti-mouse CD8α mAb (clone 2.43), or 320 µg of purified rat anti-mouse CD4 mAb (clone GK1.5) or the same volume of PBS as control. Both mAb products were produced at Division of Research Resources, CDC, Atlanta, GA. The depletion started 3 days before viral infection and continued until the experiments were completed (day 10 after viral infection). The depletion started after priming and 3 days before secondary viral challenge with lethal dose of influenza A viruses and continued until the experiments were completed (day 10 after viral infection). Flow cytometric analysis confirmed that CD8 and CD4 T cells were undetectable in lung and spleen tissues during the entire 10-day period of observation, whereas the B cell subset was not affected by either of the depletion protocols.
Influenza virus NP366 tetramers conjugated either with PE or APC were purchased from Beckman Coulter, Inc., (San Diego, CA). Immuno-staining of cells was performed as described previously  using the tetramers in combination with fluorochrome-conjugated anti-mouse CD3ε and CD3α mAb (BD Pharmingen). The results were expressed as either total numbers of tetramer+CD8+ cells per organ or the percentage of tetramer+CD8+ cells among total CD8 T cells.
The binding affinity of the NP366 peptide variants to mouse H-2 Db molecules was evaluated by measuring stabilization of MHC-I molecules on the surface of the TAP-deficient mutant cell line RMA-S according to a protocol described previously . The results were expressed as mean fluorescence intensity (MFI) of RMA-S cells incubated with serially titrated amount of NP366 peptides.
Determination of IL-2 production by the TCR transfectants
Generation of the A3-4 transfectant expressing a public TCR specific for PR8-derived NP366/Db has been described in detail elsewhere . A mouse Th1/Th2 cytokine Cytometric Bead Array (BD) was done as described previously to measure the levels of IL-2 in the culture supernatant following stimulation of the transfectant with the NP366 peptide variants in the presence of EL-4 cells as APCs. The detection sensitivity of the assay is 20 pg IL-2/ml.
Data were analyzed with unpaired t test (Prism 5, GraphPad Software, Inc.) as indicated. P<0.05 is considered statistically significant.
MHC class I-restricted immunodominant T cell epitopes of the influenza A viruses used in the present study.
(0.03 MB DOC)
MHC class II-restricted immunodominant T cell epitopes of the influenza A viruses used in the present study.
(0.03 MB DOC)
Infectivity of the virus stocks used in the present study.
(0.04 MB DOC)
NP366/Db-specific response after influenza A virus infection. B6 mice were infected intranasally with 250 MID50 of H3N2 influenza viruses as indicated. A. 10 days after primary infection, lung tissues were collected. Primary NP366/Db-specific CD8 response was examined by flow cytometry as described in detail in Material and Methods. CD3+CD8+ T cells were gated for analysis of NP366/Db+ cells. B. 40 days after primary infection, a second group of the animals were challenged intranasally with either 3 LD50 of PR8 virus or 3 LD50 of Taiwan virus. Lung and spleen tissues were collected on day 5 after lethal challenge. Memory NP366/Db-specific CD8 response was examined as described in A.
(0.44 MB TIF)
IFNγ secretion of NP366/Db-specific memory CD8 T cells. Single cells were prepared from the pooled spleen of B6 mice (5 mice per group) that were primed with x31 and subsequently challenged with lethal dose of either PR8 or Taiwan virus as described in Fig. S1. The cells were then stimulated with either 0.5 mg/ml of the NP366 peptides as indicated or no peptide in the presence of IL-2. Amino acid sequences of the NP366 peptides used are shown in table S1. After 16 hour in culture, the cells were stained with anti-mouse IFNγmAb intracellularly followed by surface staining with anti-CD3 and CD8 mAbs. CD3+CD8+ T cells were gated for flow cytometric analysis. The data are representative of two independent experiments.
(0.24 MB TIF)
We thank Dr. Paige Lawrence, University of Rochester, for kindly providing the seed stock of the NT60 virus, Biotechnology Core Facility Branch, Division of Research Resources, CDC, for assistance with peptide synthesis and production of the anti-CD8 and anti-CD4 mAb, and Ms. Catherine B. Smith, Influenza Sequencing Core, Influenza Division, CDC, for whole genome influenza virus sequencing.
Conceived and designed the experiments: WZ. Performed the experiments: WZ FL LD XL. Analyzed the data: WZ FL XL. Contributed reagents/materials/analysis tools: WZ KH ELR SS. Wrote the paper: WZ. Critical revision of the manuscript: JMK.
- 1. Schulman JL, Kilbourne ED (1965) Induction of Partial Specific Heterotypic Immunity in Mice by a Single Infection with Influenza a Virus. J Bacteriol 89: 170–174.
- 2. Epstein SL (2003) Control of influenza virus infection by immunity to conserved viral features. Expert Rev Anti Infect Ther 1: 627–638.
- 3. Yoshikawa T, Matsuo K, Matsuo K, Suzuki Y, Nomoto A, et al. (2004) Total viral genome copies and virus-Ig complexes after infection with influenza virus in the nasal secretions of immunized mice. J Gen Virol 85: 2339–2346.
- 4. Roose K, Fiers W, Saelens X (2009) Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect 22: 80–92.
- 5. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, et al. (2009) Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 5: e1000350.
- 6. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265–273.
- 7. Liang S, Mozdzanowska K, Palladino G, Gerhard W (1994) Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 152: 1653–1661.
- 8. Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, et al. (2007) Priming with Cold-Adapted Influenza A Does Not Prevent Infection but Elicits Long-Lived Protection against Supralethal Challenge with Heterosubtypic Virus. J Immunol 178: 1030–1038.
- 9. Tumpey TM, Renshaw M, Clements JD, Katz JM (2001) Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 75: 5141–5150.
- 10. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J (2001) Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 183: 368–376.
- 11. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, et al. (2007) The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25: 5086–5096.
- 12. Jameson J, Cruz J, Terajima M, Ennis FA (1999) Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162: 7578–7583.
- 13. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, et al. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82: 5161–5166.
- 14. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 3478–3490.
- 15. Roti M, Yang J, Berger D, Huston L, James EA, et al. (2008) Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 180: 1758–1768.
- 16. McMichael A (1994) Cytotoxic T lymphocytes specific for influenza virus. Curr Top Microbiol Immunol 189: 75–91.
- 17. Epstein SL (2006) Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193: 49–53.
- 18. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, et al. (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8: 796–801.
- 19. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367: 475–481.
- 20. Gorman OT, Bean WJ, Kawaoka Y, Webster RG (1990) Evolution of the nucleoprotein gene of influenza A virus. J Virol 64: 1487–1497.
- 21. Hiromoto Y, Yamazaki Y, Fukushima T, Saito T, Lindstrom SE, et al. (2000) Evolutionary characterization of the six internal genes of H5N1 human influenza A virus. J Gen Virol 81: 1293–1303.
- 22. Boon AC, de Mutsert G, Graus YM, Fouchier RA, Sintnicolaas K, et al. (2002) Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J Virol 76: 2567–2572.
- 23. Voeten JT, Bestebroer TM, Nieuwkoop NJ, Fouchier RA, Osterhaus AD, et al. (2000) Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol 74: 6800–6807.
- 24. Boon AC, de Mutsert G, van Baarle D, Smith DJ, Lapedes AS, et al. (2004) Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol 172: 2453–2460.
- 25. Crowe SR, Miller SC, Brown DM, Adams PS, Dutton RW, et al. (2006) Uneven distribution of MHC class II epitopes within the influenza virus. Vaccine 24: 457–467.
- 26. Zhong W, Reche PA, Lai CC, Reinhold B, Reinherz EL (2003) Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire. J Biol Chem 278: 45135–45144.
- 27. Belz GT, Xie W, Doherty PC (2001) Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8+ T cell responses. J Immunol 166: 4627–4633.
- 28. Crowe SR, Miller SC, Woodland DL (2005) Identification of protective and non-protective T cell epitopes in influenza. Vaccine 24: 452–456.
- 29. Meijers R, Lai CC, Yang Y, Liu JH, Zhong W, et al. (2005) Crystal structures of murine MHC Class I H-2 D(b) and K(b) molecules in complex with CTL epitopes from influenza A virus: implications for TCR repertoire selection and immunodominance. J Mol Biol 345: 1099–1110.
- 30. Lu LY, Askonas BA (1980) Cross-reactivity for different type A influenza viruses of a cloned T-killer cell line. Nature 288: 164–165.
- 31. Townsend AR, Skehel JJ (1984) The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 160: 552–563.
- 32. Klenerman P, Zinkernagel RM (1998) Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394: 482–485.
- 33. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, et al. (2003) Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9: 921–927.
- 34. Kedzierska K, Turner SJ, Doherty PC (2004) Conserved T cell receptor usage in primary and recall responses to an immunodominant influenza virus nucleoprotein epitope. Proc Natl Acad Sci U S A 101: 4942–4947.
- 35. Zhong W, Reinherz EL (2004) In vivo selection of a TCR V beta repertoire directed against an immunodominant influenza virus CTL epitope. Int Immunol 16: 1549–1559.
- 36. Zhong W, Dixit SB, Mallis RJ, Arthanari H, Lugovskoy AA, et al. (2007) CTL Recognition of a Protective Immunodominant Influenza A Virus Nucleoprotein Epitope Utilizes a Highly Restricted Vbeta but Diverse Valpha Repertoire: Functional and Structural Implications. J Mol Biol 372: 535–548.
- 37. Kendal AP, Pereira MS, Skehel JJ (1982) Concepts and procedures for laboratory-based influenza surveillance. Atlanta: Centers for Disease Control and Prevention.
- 38. Katz JM, Lu X, Young SA, Galphin JC (1997) Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis 175: 352–363.